Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1170)	6/30/2005 1:21:14 PM
From: Jibacoa	Respond to of 3722

CRGN traded at 5.34 at 9.36AM this morning (a nickel above yesterday's H <g>) The stock remains on its recent uptrend that started on June 16 from the 3.80 level in spite of higher loss for the March Q, but it had 112% better revenues.<g> Earlier this month, CRGN's subsidiary, 454 Life Sciences, presented a poster detailing its "ultra-deep sequencing" of the HIV virus, which will enable "to rapidly, reproducibly and accurately" detect minor HIV variants responsible for drug resistance. And in May, it announced and agreement between PFE and 454 Life Sciences' for its "nanotechnology-based Genome Sequencing",which reportedly enables researchers to sequence up to 100 times faster than other current platforms.The agreement calls for a 5yrs exclusive distribution by PFE and 454 could receive up to $62M in license fees,royalties and "research funding". That should hel CRGN, which has a pretty good LTD around $240M and a Debt/Equt ratio around 2.77 <g> bigcharts.marketwatch.com Bernard